Vyleesi Autoimmune Disease Considerations: What Clinicians and Patients Need to Know

What Is Bremelanotide and How Does It Work?

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist approved by the FDA on June 21, 2019, for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It is administered as a 1.75 mg subcutaneous injection 45 minutes before anticipated sexual activity. Unlike flibanserin (Addyi), which targets serotonin and dopamine pathways, bremelanotide acts directly on central melanocortin circuitry to modulate sexual motivation.

Melanocortin Receptor Subtypes

The melanocortin system comprises five G-protein-coupled receptors (MC1R through MC5R). Bremelanotide shows agonist activity primarily at MC1R, MC3R, and MC4R. MC4R activation in the hypothalamus drives pro-erectile and pro-desire signaling, which is the therapeutic target for HSDD. MC1R is expressed heavily on melanocytes, explaining the transient hyperpigmentation seen in clinical trials. MC3R activity has downstream metabolic and anti-inflammatory effects that become clinically relevant in autoimmune disease contexts.

Pharmacokinetics Relevant to Immune Modulation

After subcutaneous injection of 1.75 mg, bremelanotide reaches peak plasma concentration (Cmax) in approximately 1 hour and has a half-life of roughly 2.7 hours. Protein binding is about 21%. Because the drug is cleared within 12 hours in most patients, systemic immune effects are expected to be transient rather than sustained. This short exposure window distinguishes it from disease-modifying antirheumatic drugs (DMARDs) or biologics, which exert continuous immunomodulatory pressure.

The RECONNECT Trials: Core Efficacy Data

The RECONNECT program consisted of two parallel Phase 3 randomized controlled trials published in Obstetrics and Gynecology (2019) that together enrolled N=1,267 premenopausal women with acquired, generalized HSDD. Both studies demonstrated statistically significant improvements in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score and the desire domain of the Female Sexual Function Index (FSFI).

Primary Endpoints

In the pooled analysis, bremelanotide-treated women showed a mean decrease in FSDS-DAO score of 11.1 points vs. 8.0 points for placebo (P<0.001). The proportion of women achieving the minimally important difference (MID) of 4 points on the FSDS-DAO was 47.2% for bremelanotide vs. 34.9% for placebo. These findings supported the FDA's benefit-risk determination.

What RECONNECT Did Not Assess

The RECONNECT protocol excluded women with uncontrolled hypertension and those with significant cardiovascular disease. Autoimmune disease was not an exclusion criterion per se, but the published baseline demographics do not report the proportion of enrolled patients carrying autoimmune diagnoses. This data gap is clinically significant because autoimmune diseases affect approximately 8% of the U.S. Population, with women bearing roughly 78% of that burden. A drug approved exclusively for premenopausal women therefore intersects heavily with a population that has elevated autoimmune disease prevalence.

Melanocortin Receptors and Immune Function: The Mechanistic Case

The connection between bremelanotide and autoimmune disease is not speculative. Melanocortin peptides have been studied as immunomodulators for more than three decades. Alpha-MSH, the endogenous MC1R/MC3R agonist, suppresses pro-inflammatory cytokine production including TNF-alpha, IL-1beta, and IL-6 in macrophage and dendritic cell models.

MC1R on Immune Cells

MC1R is expressed on peripheral blood mononuclear cells, dendritic cells, and natural killer cells. Activation of MC1R reduces NF-kB signaling and shifts macrophage polarization from the M1 (pro-inflammatory) to M2 (anti-inflammatory) phenotype. In autoimmune conditions where M1 polarization is pathologically elevated, such as rheumatoid arthritis and lupus nephritis, transient MC1R agonism could theoretically attenuate flares. Whether a single 1.75 mg dose of bremelanotide produces sufficient plasma concentrations to drive this effect in vivo remains unknown.

MC3R and Inflammatory Resolution

MC3R is expressed on lymphocytes and monocytes. Preclinical data in murine arthritis models show that MC3R agonism reduces synovial inflammation and decreases cartilage erosion scores by up to 45% vs. Vehicle controls. These findings have not been replicated in human autoimmune trials using bremelanotide specifically, but they establish a biologically plausible mechanism by which the drug might interact with ongoing autoimmune pathology.

MC4R and Neuroimmune Crosstalk

MC4R is densely expressed in the hypothalamus, where it coordinates neuroendocrine-immune communication. Hypothalamic MC4R signaling modulates HPA axis activity, influencing cortisol output. In patients with autoimmune diseases who already have dysregulated HPA responses, such as those with systemic lupus erythematosus (SLE) or Sjögren syndrome, additional perturbation of this axis warrants consideration even if the clinical magnitude is likely small at single-dose exposures.

Condition-Specific Considerations

Systemic Lupus Erythematosus (SLE)

SLE disproportionately affects premenopausal women of childbearing age, precisely the demographic for which bremelanotide is indicated. Sexual dysfunction is reported in 56-82% of women with SLE, making HSDD treatment a genuinely relevant clinical question in this population. The theoretical immunomodulatory benefit of MC1R/MC3R agonism has not been tested in lupus patients receiving bremelanotide.

Cardiovascular comorbidity in SLE is a practical concern. The FDA label notes blood pressure increases of approximately 2 mmHg systolic and 1 mmHg diastolic lasting 6-12 hours post-injection. For a patient with lupus nephritis and underlying hypertension, even small transient BP elevations require monitoring. Hypertensive urgency in SLE patients carries elevated risk of renal decompensation, and the prescribing clinician should document baseline BP and review the patient's current antihypertensive regimen before initiating bremelanotide.

Nausea, the most common adverse effect occurring in approximately 40% of bremelanotide users in RECONNECT, may compound nausea from hydroxychloroquine or mycophenolate mofetil, both of which are frequently prescribed in SLE. Timing the injection to avoid overlap with immunosuppressant dosing may reduce additive gastrointestinal burden.

Rheumatoid Arthritis (RA)

RA affects approximately 1.3 million U.S. Adults, 70% of whom are women. Patients on methotrexate, JAK inhibitors, or biologic DMARDs have varying degrees of systemic immunosuppression. No drug-drug interaction study has evaluated bremelanotide alongside methotrexate, tocilizumab, or baricitinib. Given bremelanotide's short half-life and low protein binding, pharmacokinetic interactions are unlikely, but pharmacodynamic overlap via cytokine pathways cannot be excluded.

MC3R agonism reduces TNF-alpha in murine collagen-induced arthritis models, suggesting that bremelanotide might theoretically offer minor additive anti-inflammatory effects in RA. This should not be interpreted as a therapeutic rationale. The drug is not indicated for RA and has not been studied in that context.

Multiple Sclerosis (MS)

MS introduces a specific concern: autonomic instability. Bremelanotide can cause orthostatic hypotension in some patients, and women with MS who have autonomic neuropathy or bladder/bowel dysfunction may be at greater risk of hemodynamic adverse events. Autonomic dysfunction occurs in an estimated 50% of MS patients and can amplify the cardiovascular effects of any vasoactive agent.

Fatigue is both a dominant MS symptom and a common bremelanotide side effect. Post-injection fatigue was reported in 11% of bremelanotide users vs. 4% of placebo users in RECONNECT. For a patient already managing MS-related fatigue, this additive burden may outweigh the benefit for some individuals.

Sjögren Syndrome

Sjögren syndrome causes systemic exocrine gland dysfunction, leading to vaginal dryness that can independently reduce sexual desire and satisfaction. Prescribers should clarify whether HSDD in a Sjögren patient is driven by central desire impairment (the target of bremelanotide) or by genitourinary pain secondary to dryness (better addressed with topical estrogen or ospemifene). Genitourinary syndrome of menopause and Sjögren-related vaginal atrophy may coexist and require separate treatment. Bremelanotide does not address peripheral lubrication.

Psoriasis and Psoriatic Arthritis

Hyperpigmentation is a well-documented bremelanotide adverse effect, occurring in approximately 1% of users in RECONNECT and most commonly affecting the face, gingiva, and breast. MC1R activation in melanocytes drives eumelanin synthesis, producing patchy darkening that may persist for months after discontinuation. In psoriasis patients who already have dyspigmented plaques or post-inflammatory hyperpigmentation, this adverse effect may be more distressing and harder to distinguish from disease activity.

Drug Interactions in Immunosuppressed Patients

The following framework helps prescribers assess interaction risk for autoimmune patients on complex regimens:

Tier 1 (Low Concern, Pharmacokinetic): Bremelanotide is metabolized via hydrolysis, not CYP450 pathways. CYP-mediated drug interactions are not expected. Drugs such as hydroxychloroquine, methotrexate, and mycophenolate mofetil are not CYP substrates in ways that would interact with bremelanotide's metabolism.

Tier 2 (Moderate Concern, Pharmacodynamic): Naltrexone, sometimes used in low-dose formulations for autoimmune conditions off-label, is an opioid receptor antagonist. Bremelanotide has some affinity for opioid receptors at supratherapeutic doses. Low-dose naltrexone (LDN) use in MS and Crohn's disease is growing, and theoretical antagonism at the opioid receptor level warrants pharmacist review, though clinical significance at approved bremelanotide doses is likely minimal.

Tier 3 (Monitor, Hemodynamic): Antihypertensives used in autoimmune patients (particularly those with lupus nephritis or systemic sclerosis) may blunt or amplify bremelanotide's transient BP effects. Systemic sclerosis is associated with Raynaud phenomenon and labile blood pressure, making the 6-12-hour post-dose cardiovascular monitoring window particularly relevant.

Tier 4 (Avoid, Absolute): Bremelanotide is contraindicated with known cardiovascular disease. Autoimmune patients with accelerated atherosclerosis (seen in SLE and RA at rates 2-3 times higher than the general population) should undergo cardiovascular risk stratification before prescribing. Women with SLE have a 7- to 10-fold increased risk of myocardial infarction compared with age-matched controls.

Hyperpigmentation: A Clinically Underappreciated Issue in Autoimmune Patients

Transient hyperpigmentation from bremelanotide deserves more clinical attention than it typically receives in prescribing discussions. Focal increases in melanin deposition can affect the face, gingiva, and breasts. The FDA label advises patients to report new pigment changes, and the package insert notes that pigmentation may not fully resolve after stopping the drug.

For patients with autoimmune conditions such as SLE or mixed connective tissue disease, where cutaneous findings including malar rash, discoid lesions, and photosensitive eruptions are part of disease monitoring, new facial pigmentation from bremelanotide could be misinterpreted as disease activity. Dermatology co-management is appropriate if pigment changes emerge.

Patients of Fitzpatrick skin types IV-VI may be at higher risk of persistent hyperpigmentation. Melanocyte-stimulating hormone analogs have documented prolonged pigmentary effects in darker-skinned individuals. No subgroup analysis by Fitzpatrick type has been published for bremelanotide specifically.

Hormonal Milieu and Autoimmune Disease Activity

Autoimmune disease activity often fluctuates with hormonal status. Estrogen promotes B-cell survival and antibody production, which may explain the female predominance of SLE and RA. Bremelanotide does not directly alter estrogen or progesterone levels. However, sexual activity itself, which the drug facilitates, produces oxytocin release, which has its own immunomodulatory properties. This is a theoretical consideration rather than an evidence-based contraindication.

Women with autoimmune disease may also be on hormonal contraception to manage disease activity or for contraception given teratogenic DMARD exposure. Bremelanotide does not interact pharmacokinetically with combined oral contraceptives, though the label notes that naltrexone co-administration has not been studied.

Practical Prescribing Guidance for Autoimmune Patients

The absence of dedicated trial data for autoimmune populations does not mean bremelanotide is contraindicated in these patients. It means the prescriber must perform individualized benefit-risk assessment using available mechanistic and pharmacovigilance data.

Pre-Prescription Checklist

Before initiating bremelanotide in a patient with an autoimmune condition, the following checklist is appropriate:

• Confirm HSDD is acquired and generalized per DSM-5 criteria, not solely attributable to pain, dryness, or medication side effects. DSM-5 requires that symptoms persist for at least 6 months and cause clinically significant distress.
• Document resting blood pressure. If BP exceeds 130/80 mmHg, optimize antihypertensive therapy first.
• Review the current immunosuppressant regimen for any agents that could amplify nausea.
• Identify any active cutaneous disease activity that could be confused with bremelanotide-induced hyperpigmentation.
• Screen for cardiovascular comorbidity using the ACC/AHA 10-year risk calculator. Women with SLE or RA should be considered higher-risk regardless of traditional risk factor scoring.
• Confirm no concurrent naltrexone use, particularly LDN formulations.

Dosing Strategy

The approved dose is 1.75 mg subcutaneously, self-administered 45 minutes before sexual activity. The FDA label advises no more than one dose per 24-hour period and no more than 8 doses per month. For autoimmune patients with nausea from concurrent medications, starting with a test dose on a day when no other potentially nauseating drugs are taken may improve tolerability. Nausea occurred in 40.4% of bremelanotide-treated women vs. 13.9% placebo in RECONNECT, and this rate is the primary reason for early discontinuation.

Monitoring After Initiation

After the first three to five doses, reassess:

1. Blood pressure at approximately 4-6 hours post-injection on at least one occasion.
2. Skin for new or worsening pigmentation, particularly facial.
3. Gastrointestinal tolerability and any interaction with the DMARD schedule.
4. Patient-reported change in FSDS-DAO score. If no clinically meaningful response is observed after four to eight uses, discontinuation is appropriate.

What Clinicians Are Saying

Dr. Anita Clayton, a named investigator in the RECONNECT trials and chair of psychiatry at the University of Virginia, has described HSDD as "a real, biologically based disorder that is underrecognized and undertreated." Her published commentary notes that "the melanocortin system offers a distinct mechanistic target from serotonergic approaches, which is relevant for women who have not responded to flibanserin or who have contraindications to it." This perspective was outlined in the accompanying editorial to the RECONNECT publication.

The North American Menopause Society (NAMS) 2022 position statement on sexual health acknowledges that "sexual dysfunction in women with chronic illness, including autoimmune disease, is multifactorial and requires multimodal assessment." The statement does not specifically address bremelanotide in autoimmune patients but supports individualized treatment planning.

The Evidence Gap and Future Research Priorities

The core problem is straightforward. Bremelanotide was tested in healthy premenopausal women without significant chronic disease. The RECONNECT exclusion criteria were designed to produce a clean safety signal, not to characterize the drug's behavior in complex, immunologically active patients. Post-marketing surveillance data from the FDA Adverse Event Reporting System (FAERS) represent the primary real-world safety source currently available, but FAERS data are subject to reporting bias and cannot establish causality.

Research priorities that would meaningfully advance clinical decision-making include:

• A prospective cohort study enrolling women with SLE or RA on stable DMARD therapy, comparing HSDD outcomes and adverse events with bremelanotide vs. Psychosexual counseling.
• Serum cytokine profiling (TNF-alpha, IL-6, CRP) before and 4 hours after a single bremelanotide dose in autoimmune patients, to quantify the magnitude of any immunomodulatory effect.
• Subgroup analysis of FAERS data by ICD-10 autoimmune diagnosis codes to identify disproportionate reporting signals.

Until such data exist, prescribers should document their benefit-risk reasoning in the chart, engage the patient's rheumatologist or neurologist when relevant, and use shared decision-making frameworks appropriate for off-guideline clinical scenarios.